Compare Amylx Pharmaceuticals Inc (AMLX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs VanEck Vietnam ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.97 (market cap $2.64B), while VanEck Vietnam ETF trades at $17.78. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | VNM | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Sector/Thematic |
52-Week High | $24.19 | $19.80 |
52-Week Low | $7.82 | $16.34 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
VNM trades at $17.73, up 0.51% today, with a bullish technical signal driven by positive momentum indicators. The stock faces immediate resistance at $18, with support at $17. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
Outlook remains cautious due to macroeconomic headwinds in Vietnam and underperformance relative to emerging markets. Investment opportunity hinges on FTSE Russell's EM reclassification attracting foreign inflows, but risks include heatwave-induced infrastructure stress and regional capital rotation away from AI-exposed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
